Valuation: Celsion Corporation

Market Cap 76.9L 67.2L 62.01L 57.16L 1.08Cr 74Cr 1.1Cr 7.41Cr 2.92Cr 36Cr 2.89Cr 2.82Cr 124.86Cr P/E 2026 *
-0.59x
P/E 2027 * -0.8x
Enterprise Value 76.9L 67.2L 62.01L 57.16L 1.08Cr 74Cr 1.1Cr 7.41Cr 2.92Cr 36Cr 2.89Cr 2.82Cr 124.86Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-7.17%-4.39%+45.51%+79.00% 5.6TCr
+0.24%-1.54%+53.22%+71.85% 5.37TCr
+0.80%-6.31%+3.98%+423.29% 2.33TCr
-0.09%-0.01%-17.62%-14.67% 2.32TCr
-5.95%-2.58%+30.67%-9.58% 2.06TCr
-1.14%+0.03%+31.57%-30.42% 1.78TCr
-5.16%-7.00%+168.44%+306.37% 1.61TCr
-6.91%-5.83%+26.53%+636.97% 1.59TCr
+0.43%-1.03%+24.63%+191.40% 1.4TCr
Average -2.77%-0.13%+40.77%+183.80% 2.67TCr
Weighted average by Cap. -2.92%-0.73%+40.59%+144.79%

Financials

2026 *2027 *
Net sales - -
Net income -1.64Cr -1.43Cr -1.32Cr -1.22Cr -2.3Cr -158.01Cr -2.35Cr -16Cr -6.22Cr -77Cr -6.16Cr -6.03Cr -266.4Cr -2.33Cr -2.04Cr -1.88Cr -1.73Cr -3.27Cr -224.65Cr -3.34Cr -22Cr -8.84Cr -110.02Cr -8.76Cr -8.57Cr -378.75Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-